J&J (JNJ) Reports Earnings Beat, Plans 2027 Spinoff

Published on 10/13/2026 · Source: cnbc.com

AI Summary

Summarized by AI from the source below

Johnson & Johnson (JNJ) reported earnings that surpassed analyst expectations, driven by strong sales of its immune disease drug, Tremfya. The company also announced plans to spin off its hips-and-knees business, DePuy Synthes, into a standalone company by mid-2027. J&J sees a spin as creating long-term value for shareholders. Apollo Global Management is currently in talks to acquire the unit for an estimated $20 billion, according to Bloomberg.

Revenue from J&J's medical technology division rose 2.5% to $8.6 billion, falling short of the $8.71 billion analysts anticipated. International sales remained flat, affected by factors including the Middle East conflict, European austerity measures, and pricing challenges in China. Despite external pressures, the company increased its full-year sales forecast to about $101.2 billion and adjusted its earnings forecast to a midpoint of $11.10 per share.

The spin-off of DePuy Synthes reflects J&J's strategy to focus on higher-growth sectors within healthcare. This separation is likely to allow both companies to allocate resources more effectively, aiming for enhanced performance in their respective markets. For investors, the planned spin-off and raised forecasts indicate J&J's commitment to sustained growth.

Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.

Our take

Opinion from the Newsstocks AI desk, not investment advice

In our view, J&J's earnings beat and increased forecasts suggest a stable outlook despite some divisional challenges. The planned spin-off aligns with their strategic focus on high-growth sectors, which could benefit the company in the long-term. However, global pressures remain a factor to watch.

Key numbers

Quarterly pharmaceutical sales: $16.76 billion
MedTech division sales: $8.6 billion
Full-year sales forecast: $101.2 billion
Updated earnings forecast midpoint: $11.10 per share

What could help

Spin-off of DePuy Synthes can create long-term value for shareholders.

What could hurt

International sales face challenges from global conflicts and regional policies.

What to watch next

J&J remains on track for the mid-2027 separation of DePuy Synthes.

The background

A company spinoff involves creating a new, independent company from part of an existing one. This often aims to unlock value by focusing more closely on separate business areas.